Street research is expected for five companies in the week ahead.

The U.S. Securities and Exchange Commission (SEC) has approved sweeping changes to the Nasdaq Capital Market listing ...

Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

Nasdaq Inc. reports strong Q1 growth with rising revenues and EPS. Read more on how NDX is diversifying its business towards ...